Provectus Pharmaceuticals Inc. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc.

PVCT 0.0700

+1.4%

Nov 21 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: NTTG	10/29/2012 8:49:02 AM
	3 Recommendations of 13111

As feared...... if you believe the recently presented hepatocellular data 5-FU looks as effective as PV-10 at delaying un-injected tumor progression in a mouse model of hepatocellular carcinoma. Unfortunately, the highly variable mean tumor area (mm2) at time zero (from 8 to 20 by eyeball exam of the figure) and the huge SD ranges for primary injected tumor growth curves confirm that data from 4-5 mice in a treatment group is nominally informative. Unfortunate that the re-challenge data for Hepa 1-6 tumor at 50 days and B16-F10 data at 81 days in the bilateral model are 'missing'...dose-time durability of response remains unclear Not sure that this evidence is consistent with the conclusion of a PV-10 response that is tantamount to "in situ vaccination", kinda the same thinking that brought MGT to believe they could launch a NASDAQ IPO Seriously, 5 more mice in each treatment group would not have been as expensive as the attorneys, consultants, and time spent on a failed NASDAQ IPO.... Watch the moving pea, which cup is it under now?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next